A Study Of PF-05280014 [Trastuzumab-Pfizer] Or Herceptin® [Trastuzumab-EU] Plus Paclitaxel In HER2 Positive First Line Metastatic Breast Cancer Treatment (REFLECTIONS B327-02)

A Phase 3 Randomized, Double-Blind Study of PF-05280014 Plus Paclitaxel Versus Trastuzumab Plus Paclitaxel for the First-Line Treatment of Patients with HER2-Positive Metastatic Breast Cancer

Category & Conditions:
Cancer
Medicine:
TRAZIMERA FOR INJECTION(TRASTUZUMAB-QYYP)
ClinicalTrials.gov Identifier (NCT):
Protocol ID:
B3271002
Open Plain Language Summary Result:Click here